are plotted against protein levels of the BCL-2 family members (shown on the x-axis) quantifiedin untreated cell lysates from these same AML patient samples, as shown and calculated for Figure 5C . Regression analysis wasused to determine R 2 and P values.
Supplementary
Figure 2: BCL-XL modulates venetoclax response and alvocidib potentiation of venetoclax in AML models in vitro. AML cell lines with high BCL-XL expression (TF-1, HEL, MDS-L and SET-2) (A), and low BCL-XL expression (MOLM13, MV4-11, THP-1 and OCI-AML3) (B) were assessed in duplicate biological drug dose response experiments comparing venetoclax versusABT-737 +/-alvocidib. Venetoclax EC 50 values are plotted versus ABT-737 EC 50 values with increasing concentrations of alvocidib(upper panel A, B), while corresponding venetoclax or ABT-737 EC 50 fold-sensitization is plotted in the lower panel of A and B.C, TF-1 and HEL lysates prepared after treatment with non-silencing (NS) or BCL-XL siRNA were resolved by gel electrophoresis to quantify specific BCL-XL knock-down. (D), siRNA targeting BCL-XL were compared against NS siRNA in cells treated with thecombination of venetoclax and alvocidib, and EC 50 values plotted with increasing concentrations of alvocidib (data from BCL-XLsiRNA sequence 2 and sequence 9 were compiled from duplicate biological experiments each assessing four technical replicatesfor each sequence and for every dose evaluated). P values were calculated using a two-tailed Student's T-test. Figure 5B are plotted against protein levels of the BCL-2 family members (shown on the x-axis) quantifiedin untreated cell lysates from these same AML patient samples, as shown and calculated for Figure 5C . Regression analysis wasused to determine R 2 and P values. 

